Based on these studies, Salaretin is potentially useful in supporting the maintenance of blood glucose levels and may be beneficial in slowing down the progression of secondary complications of diabetes. Preliminary studies also support the beneficial role of mangiferin in reducing insulin resistance and in the maintenance of healthy blood lipid profiles.

Obesity is an important factor in the progression of diabetes complications, particularly in type 2 diabetes. A strong correlation exists between abdominal obesity and the incidence of non-insulin dependent diabetes mellitus due to the decreased peripheral insulin receptors. Conventional alpha-glucosidase inhibitors such as the anti-diabetic drugs Acarbose and Voglibose (AO-128) are suggested to be useful in preventing obesity, as evidenced by animal model studies. Further, moderate exercise increases the number of peripheral insulin receptors as well as glucose transporter proteins.

Recent laboratory data reveal that Salaretin efficiently inhibits alpha-amylase, suggesting that the extract is a "starch blocker". An amylase inhibitor acts as an anti-nutrient that obstructs the digestion of starch and absorption of glucose. Therefore amylase inhibitors are therapeutically valued in conditions such as diabetes (to reduce blood sugar levels) and in weight management. One of the conventionally used drugs in the management of diabetes, Acarbose, is a complex oligosaccharide that delays the digestion of carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following food intake. Acarbose inhibits the action of pancreatic amylase in breaking down starch, thereby achieving this effect.

In view of these findings, Salaretin is potentially useful in obesity management as well as in the management of Type II diabetes, when coupled with moderate exercise. Thus Salaretin offers multi-faceted benefits to support diabetes management.

 

© Sabinsa Corporation. 2002